3863 related articles for article (PubMed ID: 27633186)
1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP; Bain SC; Consoli A; Eliaschewitz FG; Jódar E; Leiter LA; Lingvay I; Rosenstock J; Seufert J; Warren ML; Woo V; Hansen O; Holst AG; Pettersson J; Vilsbøll T;
N Engl J Med; 2016 Nov; 375(19):1834-1844. PubMed ID: 27633186
[TBL] [Abstract][Full Text] [Related]
2. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Husain M; Birkenfeld AL; Donsmark M; Dungan K; Eliaschewitz FG; Franco DR; Jeppesen OK; Lingvay I; Mosenzon O; Pedersen SD; Tack CJ; Thomsen M; Vilsbøll T; Warren ML; Bain SC;
N Engl J Med; 2019 Aug; 381(9):841-851. PubMed ID: 31185157
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ;
N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427
[TBL] [Abstract][Full Text] [Related]
4. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM; Brown-Frandsen K; Colhoun HM; Deanfield J; Emerson SS; Esbjerg S; Hardt-Lindberg S; Hovingh GK; Kahn SE; Kushner RF; Lingvay I; Oral TK; Michelsen MM; Plutzky J; Tornøe CW; Ryan DH;
N Engl J Med; 2023 Dec; 389(24):2221-2232. PubMed ID: 37952131
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
[TBL] [Abstract][Full Text] [Related]
6. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
Nauck MA; Quast DR
Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
[TBL] [Abstract][Full Text] [Related]
11. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR; Bethel MA; Mentz RJ; Thompson VP; Lokhnygina Y; Buse JB; Chan JC; Choi J; Gustavson SM; Iqbal N; Maggioni AP; Marso SP; Öhman P; Pagidipati NJ; Poulter N; Ramachandran A; Zinman B; Hernandez AF;
N Engl J Med; 2017 Sep; 377(13):1228-1239. PubMed ID: 28910237
[TBL] [Abstract][Full Text] [Related]
12. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Bain SC; Mosenzon O; Arechavaleta R; Bogdański P; Comlekci A; Consoli A; Deerochanawong C; Dungan K; Faingold MC; Farkouh ME; Franco DR; Gram J; Guja C; Joshi P; Malek R; Merino-Torres JF; Nauck MA; Pedersen SD; Sheu WH; Silver RJ; Tack CJ; Tandon N; Jeppesen OK; Strange M; Thomsen M; Husain M
Diabetes Obes Metab; 2019 Mar; 21(3):499-508. PubMed ID: 30284349
[TBL] [Abstract][Full Text] [Related]
17. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
[TBL] [Abstract][Full Text] [Related]
19. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of intensive glucose lowering on cardiovascular outcomes.
; Gerstein HC; Miller ME; Genuth S; Ismail-Beigi F; Buse JB; Goff DC; Probstfield JL; Cushman WC; Ginsberg HN; Bigger JT; Grimm RH; Byington RP; Rosenberg YD; Friedewald WT
N Engl J Med; 2011 Mar; 364(9):818-28. PubMed ID: 21366473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
